Cyclopharm Ltd has released a press release.
Technegas Used In Multicenter COVID Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cyclopharm
- 1H 2022 Business Update - Record Revenues
- S&P DJI Announces March 2022 Quarterly Rebalance
- Cyclopharm USFDA Update
- Half Year 2021 Financial Results
- CYC First Half Trading Update
Later from Cyclopharm
- Half Year 2022 Results
- Cyclopharm Receives $1.64m R&D Refund
- Dividend/Distribution - CYC
- Technegas Enters Final Six Month USFDA Review Cycle
- USFDA Confirms Technegas Six Month Review Period
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm